Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
”Celebrating Excellence in Patient Care, Education and Research” Annual Report July 1, 2014-June 30, 2015 The Division of Hematology/Oncology The Division of Hematology/Oncology continues to be a vibrant, productive, and highly respected academic unit at the University of Michigan. With nearly 80 faculty and growing, the Division is one of the largest units in the Department of Internal Medicine. Our faculty are involved in bench to bedside research, from basic laboratory experiments to conducting experimental clinical treatments, with the goal of providing better treatment options for patients with cancer and hematologic disorders. Since 2007, when I assumed the role of Division Chief, we have recruited over 40 faculty members across multiple disease areas and research interests. We are particularly proud of the growth of our junior faculty and their remarkable accomplishments. In the last five years, our faculty have been successful in obtaining numerous awards to support their research interests, including: NIH K-awards (3), NIH R01-awards (13), Leukemia & Lymphoma Society (8), American Society of Clinical Oncology (ASCO) Young Investigator Awards (4), American Cancer Society Awards (5), the V Foundation for Cancer Research (3), American Association for Cancer Research (2), Damon Runyon Cancer Research (2), American Society for Blood & Marrow Transplantation (3), Department of Defense (8), American Society of Hematology, numerous other peer-reviewed foundation awards, and 225 new clinical trials. Below are some additional statistics showing the tremendous growth of our activities. The diverse composition of our faculty creates wonderful mentorship opportunities for our fellows across multiple disciplines and disease areas. We work with our trainees to ensure they have a strong mentorship team that will be highly committed to providing guidance for both research and career development. In addition to funding from the University of Michigan’s Graduate Medical Education Department, the trainees in our fellowship program are supported by the Veteran’s Administration, our NIH T32 Training Grant (five trainees pursuing careers in academic medicine), and the Elsa Pardee Foundation (two trainees pursuing careers in community cancer care). The majority of our graduating fellows have chosen to remain in academia, with nearly 75% of our graduating fellows in the last ten years now at an academic medical center. In this report, you will find highlights of our current faculty and fellows. We celebrate the remarkable accomplishments of the Division of Hematology/Oncology and look forward to training the future leaders in academic medicine. FY14 FY15 67 69 17 16 $19.2M $22M 458 468 54,378 57,687 New Patients 6,230 6,344 Inpatient Admissions 2,046 2,014 20 20 Faculty Kathleen A. Cooney, MD Frances and Victor Ginsberg Professor of Hematology/Oncology Professor of Internal Medicine and Urology Chief, Division of Hematology/Oncology Deputy Director, Cancer Clinical Services University of Michigan Comprehensive Cancer Center (Instruction & Clinical Tracks) Faculty (Research) External Funding (Directs) Clinical Trial Accruals Outpatient Visits Fellows FY15 Division of Hematology/Oncology Annual Report Page 1 Division Leadership The Senior Advisory Team (pictured here) helps lead the strategic direction of the division in clinical care, research, education, service, and philanthropy. Associate Chiefs The Division Leadership Team handles ongoing day-to-day management issues. This team is comprised of the division chief, Dr. Cooney, the associate chiefs, Drs. Reddy and Smith, and the division administrator, Julie Brabbs. Julie Brabbs, MBA Division Administrator Senior Advisors Daniel F. Hayes, MD, FASCO Stuart B. Padnos Professor of Breast Cancer Research Senior Advisor for Philanthropy Pavan Reddy, MD Moshe Talpaz Professor of Translational Oncology Associate Chief of Research Maha Hussain, MD, FACP, FASCO Cis Maisel Professor of Oncology Senior Advisor for Clinical Research Kemp Cease, MD, MBA Professor VA Section Chief David Smith, MD Professor Associate Chief of Clinical Services Francis Worden, MD Professor Fellowship Program Director Page 2 Moshe Talpaz, MD Alexander J. Trotman Professor for Leukemia Research Senior Advisor for Translational Research FY15 Division of Hematology/Oncology Annual Report By the Numbers—FY15 PUBLICATIONS EDUCATION 269 Journal Articles in CY 2014 20 Hematology/Oncology Fellows 23 Regularly Scheduled CME 99 Journal Articles Activities Provided in CY 2015 through July (Source: Scopus) FY15 Newly Funded Grants American Cancer Society Scholars (2) American Society of Clinical Oncology (ASCO) Young Investigator Award ABOUT US Breast Cancer Research Foundation (BCRF) (2) 85 Research & Clinical Faculty 84 Laboratory Research Staff Damon Runyon Cancer Research Foundation 37 Dedicated Administrative Staff Leukemia & Lymphoma Society 10 Buildings Occupied NIH K Award 38K sq. ft. of Research Space NIH U10 (LAPS) NIH R01 Ovarian Cancer Research Fund PATIENT CARE 57,687 Outpatient Visits 2,014 Inpatient Admissions 220 Bone Marrow Transplants $16.3M Patient Care Revenue GRANTS & CLINICAL TRIALS 227 Proposals Submitted 71 Clinical Trials Opened 468 Clinical Trial Accruals Pardee Foundation (2) Prostate Cancer Foundation U.S. Department of Defense V Foundation for Cancer Research $22M Direct Funds 6,344 New Patient Clinic Visits FY15 Division of Hematology/Oncology Annual Report Page 3 New Faculty Patrick Burke, MD—Lecturer. Dr. Burke earned his BS in Biology from Providence College in Rhode Island. He matriculated at the Mount Sinai School of Medicine in New York where he earned his medical degree. He then completed a residency in Internal Medicine at the University of Chicago Medical Center, followed by a year serving as a Chief Resident. He recently completed his Hematology/Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, where his clinical and research interests focused on leukemia, particularly adult acute lymphoblastic leukemia (ALL). He performed clinical research regarding the role of asparaginase and pediatric-inspired therapeutic regimens in adult ALL, as well as investigating therapies that spare cytotoxic chemotherapy in older adult Philadelphia chromosome-positive ALL. Dr. Burke is currently focusing his research on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies. Leslie Fecher, MD—Associate Professor. Dr. Fecher joined the faculty from Indiana University School of Medicine's Simon Cancer Center. She completed her BA in Biochemistry at Rice University in Houston, and earned her medical degree from Indiana University School of Medicine. She completed her residency at University of Texas Southwestern in Dallas, followed by an Oncology fellowship at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center in Baltimore. Dr. Fecher was an Assistant Professor at the Abramson Cancer Center in Philadelphia for four years where she held a secondary appointment in Dermatology. She then joined the faculty at Indiana University. Dr. Fecher's research and clinical focus is on melanoma and other advanced cutaneous tumors. Aki Morikawa, MD, PhD—Lecturer. Dr. Morikawa earned her BMus and MMus in Piano Performance at the Boston University School of Arts. She then completed an MPH in Epidemiology & Biostatistics at the Boston University School of Public Health, followed by a PhD in Epidemiology, and her MD from Emory University in Atlanta. Dr. Morikawa completed her Internal Medicine residency at Emory University followed by a Medical Oncology fellowship at Memorial Sloan Kettering in New York. She has already earned numerous honors, most recently the ASCO/Conquer Cancer Foundation Gianni Bonadonna Breast Cancer Research Fellowship in 2013. Dr. Morikawa’s research interest is in metastatic breast cancer with a focus in brain and leptomeningeal metastases. She is treating breast cancer patients. Phillip Palmbos, MD, PhD—Lecturer. Dr. Palmbos is a graduate of the Physician Scientist Training Program at the University of Michigan, a combined residency and fellowship program through the American Board of Internal Medicine (ABIM). His PhD research focused on DNA repair. His current laboratory research focuses on understanding the molecular mechanisms driving bladder cancer formation using transgenic and xenograft models as well as in vitro work. He is currently working in the laboratory of his mentor, Dr. Diane Simeone, in the Translational Oncology Program. His clinical focus is GU malignancy and he primarily sees patients with bladder and prostate cancers. Page 4 FY15 Division of Hematology/Oncology Annual Report New Faculty Faculty Distinction The division also welcomed back two faculty members: Ronald J. Buckanovich, MD, PhD, installed as Thomas H. Simpson Collegiate Professor Erica Campagnaro, MD—Associate Professor. Dr. Campagnaro attended Louisiana State University where she earned her BA in French, followed by an MD at Louisiana State University Health Sciences Center in New Orleans, Louisiana. She completed a residency in Internal Medicine at the University of Texas Medical Branch in Galveston, Texas, followed by a year as Chief Resident. She completed her Hematology/ Oncology fellowship at the University of Texas M.D. Anderson Cancer Center, where her clinical and research interests focused on myeloma. She continued that focus as a Clinical Lecturer at the University of Michigan from 2007-2009. She then joined the faculty at Case Western Reserve University, leading their myeloma program. Dr. Campagnaro’s clinical and research focus is on improving outcomes in patients with multiple myeloma. Ronald John Buckanovich, MD, PhD, earned an undergraduate degree in genetics and biochemistry at Cornell University in 1990, a PhD from the Rockefeller University in 1996, and a medical degree from Cornell in 1998. During his thesis research with Robert Darnell, MD, PhD, Dr. Buckanovich characterized the cellular target of an autoimmune neurologic disease associated with breast and ovarian cancer. This work resulted in a novel diagnostic test that is currently used in clinical practice. It was during his Hematology/Oncology fellowship at the University of Pennsylvania that Dr. Buckanovich worked with George Coukos, MD, PhD, and began to focus his research on defining the ovarian cancer microenvironment to identify novel therapeutic targets. Dr. Buckanovich joined the faculty of the University of Michigan in 2006. Here he has continued his efforts to define the cellular compartments of cancer in order to identify novel diagnostic tests and therapeutic agents for women’s cancer with an emphasis on ovarian cancer. Currently the laboratory is focused on understanding the cellular interactions in the tumor vascular/cancer stem cell niche. Recent studies have identified a means to inactivate BRCA gene expression in cancer cells to sensitize them to both chemotherapy and a new class of molecular targeted therapies called PARP-inhibitors. His lab is also currently developing two new therapies targeting cancer stem cells—one to prevent cancer cell metastasis and another to prevent disease recurrence. Dr. Buckanovich also maintains a busy clinical practice specializing in the treatment of ovarian and uterine cancers. He is currently the principal investigator on two clinical trials. He holds four patents, two for novel therapeutics being developed here. The author or coauthor of 37 original research articles, he was awarded a three-year Clinical Investigator Award from the Damon Runyon Cancer Research Foundation in 2008 as well as the New Innovator/Directors Award from the National Institutes of Health that same year. Bryan Schneider, MD—Associate Professor. Dr. Schneider is focused on experimental therapeutics in lung/esophageal cancer and participates in the Phase I Program. He serves as Associate Medical Director of the Cancer Center Ambulatory Care Unit (ACU) in charge of the Adult Infusion Centers and the Ambulatory Treatment Center. Dr. Schneider was a fellow at the University of Michigan from 2002-2005, and was with the division as an assistant professor until 2008. He has spent the last six years at New York Presbyterian Hospital Weill Medical College of Cornell University in New York. Dr. Buckanovich and Dean Woolliscroft FY15 Division of Hematology/Oncology Annual Report Page 5 Faculty Distinction James M. Rae, PhD, installed as Thomas H. Simpson Collegiate Professor of Cancer Research James M. Rae, PhD, holds a joint appointment in the University of Michigan Department of Internal Medicine and the Department of Pharmacology. He received a BS in biology from the University of Pittsburgh and a PhD in pharmacology from Georgetown University, where he trained with Marc E. Lippman, MD, and David A. Flockhart, MD, PhD, in the Lombardi Cancer Center. Dr. Rae was recruited to the University of Michigan in 2001 as a research investigator. Dr. Rae’s combined experiences with breast cancer research and molecular pharmacology in Drs. Lippman’s and Flockhart’s laboratories, respectively, led him to enter the field of personalized medicine. Dr. Rae has played a significant role in the field of breast cancer. He has developed an extensive network of collaborators locally, nationally, and internationally, to study how inherited genetic variants affect the way patients activate and eliminate certain drugs, in particular anti-estrogen agents such as tamoxifen and aromatase inhibitors. Dr. Rae with Dean Woolliscroft Dr. Rae is the executive officer of translational research for SWOG, the largest clinical oncology cooperative trials group in the United States. He is responsible for overseeing the group’s translational medicine efforts and biorepository, and also serves as a SWOG representative on the National Cancer Institute’s Group Banking Committee. Dr. Rae also co-chairs the Translational Breast Cancer Research Foundation’s Endocrine Resistance Working Group. Dr. Rae serves on the editorial boards of biomedical research journals and is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the American Association for the Advancement of Science, and the National Clinical Trials Network. A creative and dedicated teacher, Dr. Rae has also served as mentor to several graduate students in the Department of Pharmacology. Muneesh Tewari, MD, PhD, installed as Ray and Ruth Anderson—Laurence M. Sprague Memorial Research Professor Muneesh Tewari, MD, PhD, is a world-renowned pioneer and leader in the field of blood-based microRNA biomarkers. After earning his bachelor’s degree in biochemistry from Case Western Reserve University in 1990, he came to the University of Michigan where he earned both a doctorate in cell and molecular biology and a medical degree in 1997. He stayed on for his internship and residency in internal medicine. Dr. Tewari then moved to Boston where he completed his Oncology fellowship at Dana-Farber Cancer Institute. Following a postdoctoral research fellowship in systems biology and genetics at Dana-Farber Cancer Institute/Harvard Medical School, he joined the faculty of the Fred Hutchinson Cancer Research Center in Seattle in 2005. It was during his time at Harvard that Dr. Tewari first became intrigued by microRNAs (miRNAs). In Seattle, he focused his attention on miRNAs. His research has revealed that miRNAs are released from cancer cells into the bloodstream and circulate in a highly stable form, which has led to burgeoning interest in circulating miRNAs as biomarkers for cancer and other diseases. He continues to investigate both the biology and clinical applications of extracellular RNA, including minimally invasive methods for disease monitoring using human biofluids. Dr. Tewari has served as principal investigator for numerous grants from the NIH, the DOD, academic institutions and foundations. He has received multiple awards for innovation, including the Damon-Runyon Rachleff Innovation Award, which he received in 2009, and the Presidential Early Career Award for Scientists and Engineers awarded by President Barack Obama in 2010. A creative and dedicated mentor to his trainees, past and present, Dr. Tewari also serves on a wide variety of professional panels and committees, presents his work nationally and internationally, and maintains a clinical practice as an attending oncologist. In 2014, eager to take his work to the next step, he returned to his alma mater, a place where researchers in molecular biology and clinical oncology can intersect powerfully with those in bioengineering, tech transfer, bioinformatics, computer science, and health economics and policy. Dr. Tewari with Joseph C. Kolars, MD Page 6 FY15 Division of Hematology/Oncology Annual Report Faculty Distinction Dean’s Awards 2014 Dean’s League of Research Excellence Ivan Maillard, MD, PhD, was inducted into the Dean’s League of Research Excellence, which celebrated the phenomenal success of the U-M Medical School’s elite research faculty. Selected individuals are those that have demonstrated research excellence in all or one of the following areas: collaborations and team science, publications, seminal discoveries, entrepreneurial endeavors, and national/ international prominence in his/her field. 2014 Dean’s Faculty Awards Clinical and Health Services Research Award Moshe Talpaz, MD David C. Smith, MD Scott D. Gitlin, MD, was selected as a member of the Hematology Board of the American Board of Internal Medicine (ABIM). Maha Hussain, MD, FACP, was honored as the 2015 Giant of Cancer Care in Genitourinary Cancer. The Giants of Cancer Care program, sponsored by OncLive, celebrates individuals who have achieved landmark success within the field of oncology and is the premier oncology award in the country aiming to recognize and celebrate physicians who have made significant contributions to the cure and treatment of those living with cancer. Daniel F. Hayes, MD, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016. Mark S. Kaminski, MD, received a distinction of a unique sort. A grateful patient has named an Ann Arbor building in his honor. The building, named “The Mark” is currently under construction on Liberty Street. John Krauss, MD, is chairman elect of the American Society for Clinical Oncology (ASCO) Health Information Technology Work Group. Pavan Reddy, MD, has been elected to the Association of American Physicians (AAP). AAP membership is comprised of investigators who focus on basic, disease-oriented, patientoriented, or epidemiology research. The goals of its members include the pursuit of medical knowledge, and the advancement through experimentation and discovery of basic and clinical science and their application to clinical medicine. Muneesh Tewari, MD, PhD, has been inducted into the American Society for Clinical Investigation (ASCI). The ASCI represents active physician-scientists who are at the bedside, the research bench, and at the blackboard. The society elects up to 80 new members annually for their significant research accomplishments. Members must be 50 years of age or younger at the time of election. Therefore, election reflects accomplishments by members early in their careers. Catherine Van Poznak, MD, is chair of the Lifelong Learning Subcommittee of ASCO, and chair elect of ASCO’s Continuing Medical Education Subcommittee. Outstanding Clinician Award Gregory P. Kalemkerian, MD FY15 Division of Hematology/Oncology Annual Report Shaomeng Wang, PhD, has been named a Fellow of the National Academy of Inventors (NAI). Election as an NAI fellow is a professional distinction given to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society. Dr. Wang is an inventor on 38 issued U.S. patents and several pending patent applications, many of which have been licensed to three startup companies: Ascenta Therapeutics, Ascentage Pharma and OncoFusion Therapeutics, which Wang co-founded. Page 7 Faculty Distinction Department of Internal Medicine Awards Academiae Laureati Medici The Department of Internal Medicine’s Clinical Excellence Society, Academiae Laureati Medici, recognizes those faculty who exude and demonstrate clinical excellence towards their patients and colleagues. Anne Schott, MD was inducted into the society. Mark Kaminski, MD was re-elected as President, and Gregory Kalemkerian, MD was elected as Councilor. Division of Hematology/Oncology Annual Awards Mark Roth Award (Fellow’s Award) Lan Coffman Vedran Radojcic Division Teacher of the Year Larry Baker Sumi Sood Division Chief’s Award Moshe Talpaz, MD Shining Star Award (Fellow’s Award) Josh Wilfong Internal Medicine Faculty Award Grace Chen, MD, PhD, received the Jerome Conn Excellence in Research Award. The Jerome Conn Award is given for outstanding research investigation by a physician scientist at the assistant professor level. It is named after Jerome Conn, the former division chief of endocrinology who was the first to describe primary hyperaldosteronism later known as Conn’s syndrome. Past Hematology/Oncology Division recipients of this award include Drs. Kathleen Cooney and Pavan Reddy. Internal Medicine Staff Award Joann Sherman, HemOnc Fellowship administrator, received an Excellence in Administration award. UMHS Comprehensive Cancer Center Page 8 FY15 Division of Hematology/Oncology Annual Report Junior Faculty Achievement 2014-2015 Highlights of Grants/Clinical Trials Awarded to Junior Faculty NIH R21 (Chen) NIH R01 (Chiang) NIH K08 (Khoriaty) American Society of Clinical Oncology Young Investigator Award (Caram, Palmbos) American Society of Hematology Scholar Award (Chiang, Khoriaty) American Society for Blood and Marrow Transplantation (Magenau, Radojcic, Toubai) V Foundation for Cancer Research (Li) Concern Foundation (Chiang) Leukemia & Lymphoma Society (Wilcox) Pardee Foundation (Parkin, Magenau) Rally Foundation (Chiang) Bear Necessities (Chiang) Bayer Early Career Investigator Award (Sood) MICHR Bench to Bedside Translational Award (Khoriaty) New Clinical Trials (Alva, Burness, Cole, Magenau, Morikawa, Nguyen, Pawarode, Phillips, Sahai, Wilcox) FY15 Division of Hematology/Oncology Annual Report Selected Highlights Monika Burness, MD, received funding from MICHR (Michigan Institute for Clinical and Health Research) for her pilot project titled “Targeting Cancer Stem Cells via IL-6 Signaling in Triple-Negative Breast Cancer.” This study will lay the foundation for pivotal early phase clinical trials to evaluate the safety and efficacy of cytokine‐targeted therapy for patients with TNBC, specifically with a novel gp130 inhibitor. Dr. Burness also received the inaugural University of Michigan Comprehensive Cancer Center Dr. Frank Limpert Clinical Scholar Award. She was selected based on her novel and promising work in breast cancer stem cells. Additionally, she received a University of Michigan Health System Lefkofsky Family Foundation Scholar Award. Phillip Palmbos, MD, PhD, focuses his research on understanding the molecular drivers of bladder cancer formation. He has identified the oncogene, ATDC/TRIM29, as important driver in invasive basal bladder tumors where it promotes tumor growth and invasion. He was awarded the ASCO Young Investigator Award for this work in 2014, and received the Miriam Gleberman Young Investigator Award from the Bladder Cancer Advocacy Network (BCAN). Dr. Palmbos’ lab is located at the NCRC in the Translational Oncology Program. Brian Parkin, MD, focuses his research on translational genomics of acute myelogenous leukemia (AML), specifically the association of genomic aberrations with relapsed and chemorefractory AML, as well as the development of novel methods of genomic minimal residual disease detection. He published “Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia” in the journal Clinical Cancer Research this year, which examined the interplay of gene mutations and DNA copy number aberrations and their effect on clinical outcomes. He was the recipient of the American Society of Blood and Marrow Transplantation New Investigator Award in 2013 and received a grant from the Pardee Foundation in 2014 to further his work studying rare variant detection and clonal dynamics of AML in complete remission. Page 9 Education Fellowship Program ACGME Fellowship Program in Hematology/Oncology Trainees rotate through inpatient services and outpatient continuity clinics and have the opportunity to focus on a research project with a faculty mentor. Dr. Francis Worden directs this program, along with Drs. Dale Bixby and Patrick Hu, who serve as associate directors. We thank Dr. Ronald Buckanovich for his service and leadership as associate director for the last six years. L-R: Drs. Bixby, Buckanovich, Hu and Worden We prepare our fellows to be creative and productive contributors as both cutting-edge researchers and astute clinicians. This is evidenced by a number of our trainees having abstracts accepted for publication or presentation at the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), or the American Association for Cancer Research (AACR) annual meetings. Our program combines well-rounded clinical training with the opportunities to work with world-class investigators in a collegial environment. Our combined Hematology/Oncology three-year clinical training program features a diversified patient care experience on busy hematology and oncology inpatient services, consultative services, the bone marrow transplantation program, and outpatient clinics at the University of Michigan Comprehensive Cancer Center and the nearby Ann Arbor Veterans Affairs Medical Center. Educational Programs Undergraduate and Graduate Students Many of our faculty are involved in the education of students interested in scientific research careers through the U-M Medical School’s Undergraduate Research Opportunity Program (UROP) which is designed to build partnerships with first/second year students and faculty researchers. Our faculty also participate in: Program in Biomedical Sciences (PIBS) Accreditation Council for Graduate Medical Education (ACGME) Residency Program in Internal Medicine Our faculty teach residents in multiple settings, including inpatient services, outpatient clinics, and in clinical and laboratory research activities. U-M Medical Students: Dr. Asra Ahmed leads the Hematology sequence for second year medical students. Medical Scientist Training Program (MSTP) Graduate Program in Immunology Graduate Program in Cancer Biology Biological Sciences Scholars Program (BSSP) Global Health Initiative/Global Reach Many of our faculty also have established both formal and informal mentorship relationships with undergraduate, graduate and post-doctoral students. Page 10 Faculty Development: Drs. Asra Ahmed and Rashmi Chugh both serve on the Internal Medicine Education Committee which is charged with developing a faculty development process centered on education. FY15 Division of Hematology/Oncology Annual Report HemOnc Fellows 2015 Graduating Fellow Destinations University of Michigan Cancer Center Elizabeth Davis, MD Sumana Devata, MD Raymond Esper, MD, PhD Vedran Radojcic, MD Washington University Leonel Hernandez Aya, MD Stanford University Palliative Fellowship Joshua Wilfong, DO Fellowship website: http://www.med.umich.edu/intmed/hemonc/fellows/index.html FY15 Division of Hematology/Oncology Annual Report Page 11 Patient Care CLINICAL SERVICES Inpatient Clinical Services University Hospital Oncology (Internal Medicine Residency Service) Hematology (Internal Medicine Residency Service) Chemotherapy Service C.S. Mott Children’s and Von Voigtlander Women’s Hospital (C&W) Blood and Marrow Transplant (Non-Residency Service) Hematology (Non-Residency Service) Acute Leukemia Outpatient Clinical Services Comprehensive Cancer Center, Ann Arbor CCC Team 1 (Adult Hematology) CCC Team 2 (Medical Oncology) CCC Team 3 (GU Oncology) CCC Team 5 (Breast Oncology) CCC Team 6 (Melanoma, Genetics) CCC Team 7 (Gynecological Oncology) Infusion Services C. S. Mott Children’s & Von Voigtlander Women’s Hospital (C&W) Adult Blood & Marrow Transplant Adult Acute Leukemia Clinic Infusion Services Canton & Northville Health Centers Hematology Oncology Infusion Services Page 12 New Clinic Locations Northville—opened July 15, 2014. The new Northville Health Center opened July 15, 2014. The new facility boasts 100,000 square feet of clinical and diagnostic space. An estimated 160 patients were seen in FY15 at this new location where a full suite of Hematology and Oncology services are offered. Dr. Albert Quiery oversees hematology patients and Dr. John Krauss oversees oncology patients. Dr. Krauss is Medical Director, Canton and Northville Infusion Services. In March of 2015, our Adult Acute Leukemia Clinics moved to the C.S. Mott Children’s and Von Voightlander Women’s Hospital to more closely align with the services provided there by the Blood and Marrow Transplant Group. New Thyroid Cancer Research website A new website devoted to thyroid cancer research at the U-M Health System called ThyCare (THYroid CAncer REsearch), has been developed to give visibility to the program and information to patients. The website highlights the staff, faculty, and students working on thyroid cancer projects, as well as their publications, and research news. The thyroid cancer research group is represented by two teams, which are profiled on the website: the Thyroid Cancer Health Services Research Team, headed by Megan Haymart, MD, and the Thyroid Cancer Clinical Trials Team, headed by Francis (Frank) Worden, MD. The web address for the new site is: https://sites.google.com/a/umich.edu/thycare/home. FY15 Division of Hematology/Oncology Annual Report Drug Discovery About the Program These faculty are working on drug discovery, pharmacogenetics and pharmacogenomics. Shaomeng Wang, PhD, runs a substantial laboratory on the NCRC campus conducting drug design, synthesis, and development of smallmolecule therapeutics for the treatment of human cancers, as well as development of new computational methods of drug design. Selected Publications Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, Aguilar A, Dos-Santos O, Besret L, Guerif S, Pannier P, Gorge-Bernat D, Debussche L. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. Epub 2014 Aug 21. PMID 25145672 Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem. 2015 Feb 12;58(3):1038-52. Epub 2014 Nov 14. Review. PMID 25396320 Hoffman-Luca CG, Ziazadeh D, McEachern D, Zhao Y, Sun W, Debussche L, Wang S. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. Clin Cancer Res. 2015 Jun 1;21(11):2558-68. Epub 2015 Mar 9. PMID 25754349 Muneesh Tewari, MD, PhD holds a secondary appointment with the Department of Biomedical Engineering and is also a member of the Biointerfaces Institute and Center for Computational Medicine & Bioinformatics (CCMB). Dr. Tewari’s laboratory is best known for its discoveries in the biology of extracellular microRNAs. His groundbreaking research bridges disciplines including molecular biology, clinical oncology, bioengineering and computer science. His team is focused on reducing cancer mortality by developing a next generation of biomarker approaches to enable earlier detection of cancer, more effective use of new therapies such as immunotherapy, and improved non-invasive methods for long-term follow-up and care of cancer survivors. They are accomplishing this by bringing together concepts and approaches from molecular oncology, engineering, and information technology, to enable cancer detection and monitoring to be done non-invasively at home, in an internet-connected way over extended periods of time. Dr. Tewari received a $3.3 million U01 grant from the NIH Extracellular RNA Communication Program to characterize extracellular RNA in body fluids from healthy individuals using next generation sequencing methods. The purpose of this five-year project is to discover the universe of extracellular RNAs present in healthy people, as well as to study the absorption of RNA ingested in food into the circulation of healthy individuals. Co-Investigators on the study include Drs. Hui Jiang, Saravana Dhanasekaran and Arul Chinnaiyan at U-M, as well as Drs. Florian Hladik, Johanna Lampe and Julie McElrath the Fred Hutchinson Cancer Research Center in Seattle, WA. Selected Publication Chevillet JC, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyane EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M. Quantitative and stoichiometric analysis of the microRNA content of exosomes. PNAS (USA), 2014; 111 (41): 14888-93. Epub 2014 Sep 29. PMID 25267620 FY15 Division of Hematology/Oncology Annual Report Page 13 Experimental Therapeutics About the Program Phase I Faculty This past year brought many changes to the Phase I program. There has been a significant increase in patients being referred to open slots in accruing Phase I clinical trials. Monthly meetings are utilized to further develop and refine this novel program. Monika Burness, MD, is investigating novel therapies to improve treatment options for patients with breast cancer. During FY15, Phase I researchers opened 15 clinical studies and enrolled 76 patients Rashmi Chugh, MD, is actively engaged in clinical trials in connective tissue oncology and experimental therapeutics. Bryan Schneider, MD, has a strong background in clinical and translational studies with interests in the area of diagnosis and novel treatment for lung cancer. Selected Publications Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27. PMID 25716544 Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14;124(7):1038-46. PMID 24920586 Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs. 2015 Jun;33(3):652-63. doi: 10.1007/s10637-015-0230-x. Epub 2015 Mar 18. PMID 25777468 Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295303. doi: 10.1158/1078-0432.CCR-14-1373. Epub 2014 Oct 16. PMID 25324140 Page 14 Top Row: Drs. Burness, Chugh and Schneider Bottom Row: Drs. Phillips, Smith and Talpaz Tycel Phillips, MD, is conducting experimental therapeutics with a focus on hematologic malignancies. David Smith, MD, is a physician investigator conducting experimental therapeutics in addition to his other clinical and leadership responsibilities. Moshe Talpaz, MD, is a clinical investigator conducting experimental therapeutics in addition to his other clinical and leadership responsibilities. FY15 Division of Hematology/Oncology Annual Report Hematology About the Program Our 21 active program faculty engage in patient care, educational activities, and research related to benign and malignant hematology. Among our specialists are faculty who focus on specific disease groups: blood and coagulation disorders, myeloproliferative neoplasms, myelofibrosis, lymphoma, leukemia and myeloma. Our researchers are exploring exciting opportunities in the areas of disease prevention, understanding predictive and diagnostic biomarkers related to disease progression, and identification of molecular targets to develop novel therapeutic treatments of patients with hematologic diseases. Selected Publications Burgess MR, Hwang E, Firestone AJ, .. Li Q. Preclinical efficacy of MEK inhibition in Nras mutant AML. Blood. 2014 Dec 18;124(26):3947-55. PMID 25361812 Contreras-Galindo R, Kaplan MH, Dube D, Gonzalez-Hernandez MJ, Chan S, Meng F, Dai M, Omenn GS, Gitlin SD, Markovitz DM. Human Endogenous Retroviruses Type-K (HERV-K) virus particles package and transmit HERV-K-related sequences. J Virol. 2015 Jul;89(14):7187-201. PMID 25926654 Jones M, Chase J, Brinkmeier M, Xu J, Weinberg DN, Schira J, Friedman A, Malek S, Grembecka J, Cierpicki T, Dou Y, Camper SA, Maillard I. Ash1 controls quiescence and self-renewal potential in hematopoietic stem cells. J Clin Invest. 2015 May;125(5):2007-20. Epub 2015 Apr 13. PMID 25866973 Hematology researchers opened 16 new clinical trials and enrolled 83 patients Kocak H, Ballew BJ, Bisht K, .. Suman S, O’Neil A, Giri N, NCI DCEG Cancer Genomics Research laboratory, NCI DCEG Cancer Sequencing Working Group, Maillard I, Alter BP, Keegan CE, Nandakumar J, Savage SA. HoyeraalHreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1. Genes Dev. 2014 Oct 1;28(19):2090-192. Epub 2014 Sep 18. PMID 25233904 Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small molecule inhibitor as therapy for B-cell malignancies. Blood. 2015 Jun 4;125(23):3588-97. Epub 2015 Mar 26. PMID 25814533 Stein BL, Gotlib J, Arcasoy, M, Nguyen MH.. Talpaz M, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. JNCCN. 2015 Apr;13(4):424-34. PMID 25870379 Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015 Apr;94 Suppl 2:s195-207. Epub 2015 Mar 27. PMID 25814086 Yildiz M, Li H, Bernard D, Amin NA, Ouillette P, Jones S, Saiya-Cork K, Parkin B, Jacobi K, Shedden K, Wang S, Chang AE, Kaminski MS, Malek SN. Activating STAT6 mutations in follicular lymphoma. Blood. 2015 Jan 22; 125(4):668 -79. Epub 2014 Nov 26. PMID 25428220 FY15 Division of Hematology/Oncology Annual Report Page 15 Hematology Faculty Asra Ahmed, MD, is a medical hematologist with a clinical focus on lymphoma, myeloma and coagulation disorders. Dr. Ahmed also directs the second year medical student hematology sequence. Dale Bixby, MD, PhD, specializes in clinical research to develop therapeutic trials for the treatment of leukemia. He also serves as co-director of the fellowship program for the division and is the director of Inpatient Hematology. Paula Bockenstedt, MD, specializes in general hematology with emphasis in autoimmune hematologic disorders and disorders of hemostasis such as ITP, antiphospholipid syndrome, thrombophilia and hemophilia. Dr. Bockenstedt is the director of the Adult Coagulation Disorders Program and participates in multi-center studies of thrombosis, antiphospholipid antibody syndrome (APLS) and congenital hemophilic disorders. Patrick Burke, MD—Dr. Burke is currently focusing his research on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies in the Cancer Center. Erica Campagnaro, MD, is focused on clinical research to improve outcomes in patients with multiple myeloma. Page 16 Mark Chiang, MD, PhD, sees patients with hematologic malignancies. His research program is focused on leukemia, notch signaling, hox transcription factors, leukemia stem cells, and mouse modeling. Craig Cole, MD, specializes in multiple myeloma and consultative general hematology. His research is focused on developing clinical trials for multiple myeloma. Scott Gitlin, MD, treats patients with all types of malignant and non -malignant hematologic disorders, including bleeding and clotting diseases and other hematologic disorders. His laboratory research focuses on the role of viruses in oncogenesis. Mark Kaminski, MD, treats lymphoma patients and conducts clinical research focused on developing therapeutic trials for the treatment of lymphoma. He is internationally known for his work in radioimmunotherapy (RIT). Dr. Kaminski is the director of the Multidisciplinary Lymphoma Clinic. Rami Khoriaty, MD, is pursuing research focused on understanding the pathophysiology of congenital dyserythropoietic anemias and the process of erythropoiesis. Dr. Khoriaty treats patients with myeloproliferative neoplasms and other myeloid neoplasms. Lisa Kujawski, MD, is a hematologist with a clinical and research focus on the treatment of myelodysplastic syndromes and acute/ chronic leukemias, palliative medicine and symptom management. FY15 Division of Hematology/Oncology Annual Report Hematology Faculty Qing Li, MD, PhD, conducts research focused on signaling pathways in normal hematopoietic stem cells and leukemic stem cells. She treats patients with hematologic malignancies. Albert Quiery, Jr., MD, is the director of General Hematology in the Cancer Center, and the Team One Leader in the Cancer Center. His clinical focus is in the areas of immunohematology, hemoglobinopathies, hemostasis, and thrombosis. His academic interest is in bioethics and the medical humanities. Dr. Quiery sees patients at the Cancer Center and the new Northville Health Center. Ivan Maillard, MD, PhD, is a member of the Life Sciences Institute where he researches hematopoiesis, hematopoietic stem cells, Notch signaling, and T-cell immunity. He treats patients with hematological malignancies and directs the University of Michigan’s Leukemia Program. Samuel Silver, MD, PhD, FASCO, specializes in bleeding disorders, platelet dysfunction, porphyria, myeloproliferative and myelodysplastic disorders, as well as quality of care. Dr. Silver also serves as Assistant Dean for Research, U-M Medical School. Sami Malek, MD, treats patients with leukemia. His laboratory focuses on genetics and bio-markers related to chronic lymphocytic leukemia (CLL) and lymphoma and the identification of targeted therapeutic treatment options. Suman Sood, MD, treats patients and conducts research related to thrombosis, acquired hemophilia, bio-markers of venous thrombosis, novel anticoagulants, and bleeding disorders in women. Marie Huong T. Nguyen, MD, treats patients with hematologic malignancies, with a clinical focus on myeloproliferative neoplasms (MPNs). Her research focuses on early phase clinical trials in myelofibrosis and other MPNs. Moshe Talpaz, MD, treats leukemia patients and conducts clinical research on hematologic malignancies, particularly leukemia, to develop novel therapeutic options for patients. Tycel Phillips, MD, treats patients with lymphoma. He conducts clinical research related to lymphomas and Phase I/II studies. FY15 Division of Hematology/Oncology Annual Report Ryan Wilcox, MD, PhD, treats patients with lymphomas. His research is focused on understanding the T-cell lymphomas and the role of host immunity in lymphoproliferative disorders. Page 17 Blood & Marrow Transplant Program About the Program The Adult Blood & Marrow Transplantation (BMT) Program, is headed by Pavan Reddy, MD, the Moshe D. Talpaz Professor of Translational Oncology. He is also serving as the clinical director of Adult BMT. The Division welcomed Claudia Diaz-Byrd as the new BMT Program Administrator in 2014. The BMT Program performs over 220 transplants per year. Our BMT researchers continue to maintain a prominent presence at national meetings, including the American Society of Blood and Marrow Transplantation/Center for International BMT Research and the American Society of Hematology. The Program has piloted an Ambulatory Treatment Center (ATC) which concentrated care of early post-transplant for autologous patients through day 30 and through day 100 for allogeneic patients. This has impacted outcomes with a reduction in readmission rate. The Program includes an extracorporeal photopheresis (ECP) unit that is one of the largest in the world. Selected Publications Choi SW, Gatza E, Hou G, Sun Y, Whitfield J, Song Y, Oravecz-Wilson K, Tawara I, Dinarello CA, Reddy P. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2015;125(5):815-9. Epub 2014 Nov 28. PMID 25428224 Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versushost disease. Nat Reviews Clin Oncol. 2014;11(9):536-47. Epub 2014/06/25. doi: 10.1038/nrclinonc.2014.102. PMID 24958183 Keusch F, Rao R, Chang L, Lepkowski J, Reddy P, Choi SW. Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20 (10):1604-11. Epub 2014 Jun. doi: 10.1016/j.bbmt.2014.06.020. PMID 24972252 Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC . Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015;94(6):1033-41. Epub 2015 Mar19. doi: 10.1007 s00277-015-2349-4. PMID 25784222 Sun Y, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, Liu C, Toubai T, Wu J, Rossi C, Braun T, Saunders T, Reddy P . Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015;125(7):2825-40. Epub 2015 Jun 23. doi: 10.1172/jci78753. PMID 26098216 Sun Y, Wang Y, Toubai T, Oravecz-Wilson K, Liu C, Mathewson N, Wu J, Rossi C, Cummings E, Wu D, Wang S, Reddy P. BET bromodomain inhibition suppresses graftversus-host disease after allogeneic bone marrow transplantation in mice. Blood. 2015;125(17):2724-8. Epub 2015 Mar. doi: 10.1182/blood-2014-08-598037. PMID 25778533 BMT researchers opened three new clinical trials and enrolled 39 patients Page 18 FY15 Division of Hematology/Oncology Annual Report BMT Faculty Steven Goldstein, MD, specializes in stem cell transplantation and conducts clinical research in the treatment of hematologic malignancies and the prevention and treatment of GVHD. Attaphol Pawarode, MD, specializes in stem cell transplantation and conducts clinical research in BMT for lymphoid diseases. John Magenau, MD, specializes in stem cell transplantation and conducts clinical research in the treatment of complications and prevention of relapse after BMT. Pavan Reddy, MD, specializes in stem cell transplantation and conducts translational and laboratory research focused on blood and marrow transplantation, specifically in GVHD and graft-versus-leukemia (GVL). Brian Parkin, MD, specializes in the treatment of acute myeloid leukemia (AML) and bone marrow transplantation. He conducts laboratory research focusing on genomic biomarker discovery and validation as well as determining the mechanisms of therapy resistance and relapse of AML before and after allogeneic stem cell transplantation. FY15 Division of Hematology/Oncology Annual Report C.S. Mott Children’s and Von Voigtlander Women’s Hospitals—home of the BMT Clinical Service. Mary Mansour Riwes, DO, specializes in stem cell transplantation and conducts clinical research in leukemia and hematopoietic stem cell transplantation. Page 19 Gastrointestinal (GI) Oncology About the Program Seven division faculty clinicians and researchers, working with colleagues across other disciplines, are part of the Gastrointestinal (GI) Oncology Program. The program is focused on the care and treatment of patients with colorectal, pancreatic, gastric, and liver malignancies. The research program is just as collaborative as the clinical program. It includes more than 40 researchers from 18 departments who have made significant strides in researching GI cancers. Their goal has been focused upon what biologic, genetic and/or molecular processes have to take place to give rise to the development of GI cancer. In 2010, the program received a Gastrointestinal Oncology Specialized Program of Research Excellence (SPORE) grant from NIH. The overall goal of this SPORE is to reduce mortality associated with GI cancers, specifically colorectal and pancreatic cancers. This goal will be achieved through identifying and developing interventions to modify molecular based common cancer-associated carcinogenesis and cancer progression processes and linking them to human investigations. Page 20 Selected Publications Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM. Pilot clinic trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23): 5937-45. PMID 25278454. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: A pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. 2014 Jul 25 Epub ahead of print. PMID 25068471. Seregin SS, Chen GY, Laouar Y. Dissecting CD8+ NKT cell responses to listeria infection reveals a component of innate resistance. J Immunol. 2015 Aug 1;195(3): 1112-20. Epub 2015 Jun 26. PMID 26116500 Veenstra CM, Regenbogen SE, Hawley ST, Griggs JJ, Banerjee M, Kato I, Ward KC, Morris AM. A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care. 2014 Nov; 52(11):957-62. PMID 25304021 Veenstra CM, Epstein AJ, Liao K, Griggs JJ, Pollack CE, Armstrong KA. Hospital academic status and value of care for non-metastatic colon cancer. J Oncol Pract. 2015 May;11(3):e30412. Epub 2015 Apr 21. PMID 25901052 FY15 Division of Hematology/Oncology Annual Report GI-Oncology Faculty Dean Brenner, MD, Kutsche Memorial Chair of Internal Medicine Professor, specializes in GI oncology and cancer prevention. He is the principal investigator of an NCI-sponsored GI SPORE as well as an NCI Early Detection Research Network (EDRN) grant. Grace Chen, MD, PhD, conducts laboratory research investigating the role of the immune system and gut bacteria in colon cancer development, and also specializes in the treatment of patients with GI malignancies. Patrick Hu, MD, PhD, conducts laboratory research focused on c. elegans as a model for studying the pathogenesis of cancer. His clinical interest is in colorectal cancer. Vaibhav Sahai, MD, MS, focuses on patients with GI cancers. His research focus lies in experimental therapeutics in pancreatic and biliary tract cancer via a molecular-biology based approach in the laboratory with the aim to perform clinical and translational research. Christine Veenstra, MD, specializes in patients with GI malignancies. Her research is focused on identifying factors that impact the quality of colorectal cancer care, and on developing interventions to improve the receipt of high quality care. GI-Oncology researchers opened seven clinical trials in FY15 and enrolled 57 patients Mark Zalupski, MD, conducts clinical research to develop therapeutic treatment options for GI cancers and is a senior leader in the GI Clinic. John Krauss, MD, sees general oncology patients at the Canton and Northville clinics, and colon cancer patients at the Cancer Center. Dr. Krauss is Medical Director, Infusion Services, Canton & Northville Health Centers. FY15 Division of Hematology/Oncology Annual Report Page 21 Genitourinary (GU) Oncology About the Program The UMCCC has an NIH SPORE for Prostate Cancer which provides research support for a substantial amount of translational research conducted by faculty from multiple disciplines: Urology, Surgery, Radiation Oncology and Pathology. Selected Publications Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M, Lee C, Hafez K, Hollenbeck B, Weizer A, Premasekharan G, Tran T, Fu C, Ionescu-Zanetti C, Schwartz M, Fan A, Paris P. Circulating tumor cells as potential biomarkers in bladder cancer. J Urol. 2015 Sep;194(3):790-8. Epub 2015 Apr 23. PMID 25912492 Beebe-Dimmer JL, Hathcock M, Yee C, Okoth LA, Ewing CM, Isaacs WB, Cooney KA, Thibodeau SN. The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. Cancer Epidemiol Biomarkers Prev. Epub ahead of print 2015 Jun 24. PMID 26108461 Brisset JC, Hoff BA, Chenevert TL, Jacobson JA, Boes JL, Galbán S, Rehemtulla A, Johnson TD, Pienta KJ, Galbán CJ, Meyer CR, Schakel T, Nicolay K, Alva AS, Hussain M, Ross BD. Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer. PLoS One. 2015 Apr 10;10 (4):e0123877. eCollection 2015. PMID 25859981 Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2014 Sep 1;120(17):2735-41. Epub 2014 May 19. PMID 24842808 Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee S, Lin HM, George DJ. Investigational single agent orteronel (TAK-700) in patients with nonmetastatic castrationresistant prostate aancer and rising prostate-specific antigen: A Phase II study by the Prostate Cancer Clinical Trials Consortium. Clin Cancer Res. 2014 20:4218-27. PMID24965748 Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS. A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015 Sep;51(13):1714-24. Epub 2015 Jun 13. PMID 26082390 GU-Oncology researchers opened ten clinical trials in FY15 and enrolled 56 patients Page 22 Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson, Jr. SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2015 May 10;33 (14):1601-08. Epub 2015 Apr 6. PMID 25847934 FY15 Division of Hematology/Oncology Annual Report GU-Oncology Faculty Ajjai Alva, MD, treats patients and conducts clinical research focused on genitourinary (GU) oncology, including prostate, bladder and kidney cancers. He currently has a UM Michigan Institute for Clinical & Health Research (MICHR) K Award supporting his research. Phillip Palmbos, MD, PhD, is conducting research on DNA repair. His current laboratory research focuses on understanding the molecular mechanisms driving bladder cancer formation using transgenic and PDX models as well as in vitro work. His clinical focus is GU malignancy and he primarily sees patients with bladder and prostate cancers in the Cancer Center. Megan Caram, MD, conducts research investigating minimizing the harm done to patients with cancerdirected therapies and understanding the factors that guide treatment decisions. She is currently studying the variation in care of castration-resistant prostate cancer, including non-evidence-based use of therapies, and investigating the clinical and nonclinical factors that guide treatment decisions, including patients' access to care and provider effects on various treatment decisions. Kathleen Cooney, MD, Frances and Victor Professor of Hematology/Oncology, conducts research related to prostate cancer genetics and treats patients with prostate cancer. She is a PI of an NCI T32, Co-PI of the U-M Prostate Cancer SPORE, PI of a DOD award, and member of the steering committee for the International Consortium for Prostate Cancer Genetics. Bruce Redman, DO, treats patients and conducts clinical research related to GU cancers and melanoma. His research is directed at the development of novel therapeutic treatment options for both GU cancers and melanoma. David Smith, MD, treats patients with testicular, prostate and bladder cancer and advanced solid tumors. His research interest is in novel therapeutics and clinical trial design. He is the PI of multiple clinical trials aimed at the development of new therapeutic options for patient with advanced solid tumors. Maha Hussain, MD, FACP, FASCO, Cis Maisel Professor of Oncology, professor of Medicine and Urology, treats patients with prostate, bladder and testes cancer. Her clinical research is focused on the development of novel therapeutics for prostate and bladder cancer and is funded by federal, foundation and pharmaceutical grants and contracts. FY15 Division of Hematology/Oncology Annual Report Page 23 Head & Neck and Thoracic Oncology About the Program Selected Publications The UMCCC has an NIH SPORE for Head and Neck (H&N) cancer which strengthens the program by providing support for exciting new research projects. Head and neck cancer researchers work closely with colleagues across other disciplines: otolaryngology, radiation oncology, and speech pathology. Our thoracic oncology faculty focus on conducting research in close collaboration with colleagues in thoracic surgery, pulmonary, gastroenterology, radiology and pathology. Dr. Ramnath conducts a clinical research program at the Veterans Affairs Ann Arbor Healthcare System (VAAAHS). Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area. Ophthal Plast Reconstr Surg. 2015 Feb 11. Epub ahead of print. PMID 25675162 H&N researchers opened five clinical trials in FY15 and enrolled 46 patients Thoracic researchers opened four new clinical trials and enrolled 14 patients Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Gannon J, Adjei AA, Adjei AA, Ramnath N. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. J Thorac Oncol. 2014 Feb;9(2):222-30. PMID 24419420 Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, Chang AC, Beer DG, Chen G. A MicroRNA cluster at 14q32 drives aggressive lung adenocardinoma. Clin Cancer Res. 2014 Jun 15;20 (12):3107-17. Epub 2014 May 15. PMID 24833665 Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG, Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2014 Oct;9(10):1513-22. PMID 25170638 Ramnath N, Nadal E, Jeon CK, Sandoval J, Colacino J, Rozek LS, Christensen PJ, Esteller M, Beer DG, Kim SH. Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma. J Thorac Oncol. 2014 Apr;9(4):473-82. PMID 24736069 Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, Fouladdel S, Chang AC, Lin L, Jiang H, Waghray M, Luker G, Simeone DM, Wicha MS, Beer DG, Ramnath N*, Nagrath S. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014 Dec 15;5(23):12383-97. PMID 25474037 (*co-corresponding author) Page 24 FY15 Division of Hematology/Oncology Annual Report Head & Neck and Thoracic Faculty Khaled Hassan, MD, MS, treats patients with lung cancer. His research lab is focused on lung cancer stem cells and establishing targeted therapy to improve patient outcomes. Gregory Kalemkerian, MD, conducts clinical research focused on developing therapeutic trials for the treatment of lung cancer. He is a senior leader in the Thoracic Oncology Clinic. Nithya Ramnath, MD, has a joint appointment with VAAAHS. She treats patients with lung cancers. Her laboratory research interests include studying regulation of vitamin D metabolism in smoking-related lung cancers. Additionally, she has a research interest in determining ex-vivo predictors of drug sensitivity (for targeted therapy) using circulating tumor cells derived from patients. Her clinical research interests include studying determinants of response to immunotherapy in lung cancer. At the VAAAHS, she is co -PI of a Lung Cancer Screening Demonstration Project and site PI for Precision Oncology Program for Veterans with cancer. FY15 Division of Hematology/Oncology Annual Report Bryan Schneider, MD, is focused on experimental therapeutics in lung/esophageal cancer and participates in the Phase I Program. He serves as Associate Medical Director of the Cancer Center Ambulatory Care Unit (ACU) in charge of the Adult Infusion Centers and the Ambulatory Treatment Center. Susan Urba, MD, is the Medical Director of the UMCCC Symptom Management & Supportive Care Program. She conducts clinical research related to esophageal cancer, head and neck cancer, and palliative care. Francis Worden, MD, conducts clinic research directed at the development of novel therapeutic treatment options for patients with adrenal and head and neck cancers. Page 25 Breast & Gynecologic Cancers About the Program Selected Publications We have twelve faculty dedicated to women’s cancers in the Division of Hematology/Oncology focusing on breast cancer and gynecologic oncology. Academic interests span the spectrum of disease, including risk and prevention, adjuvant systemic therapy, new drug development, tumor biomarker generation and evaluation, quality of life studies, and health sciences research Cardoso F, Costa A, Norton L, Senkus E .. Merajver SD, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014 Oct; 25(10): 1871-88. Epub 2014 Sep 18. PMID 25234545 Chen YC, Allen SG, Ingram PN, Buckanovich R, Merajver SD, Yoon E. Single cell migration chip for chemotaxisbased microfluidic selection of heterogeneous cell populations. Sci Rep. 2015 May 18; 5:9980. PMID 25984707 Conley SJ, Baker TL, Burnett JP, Thiesen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150 (3):559-67. Epub 2015 Apr 2. PMID 25833208 Deng L, Shang L, Bai, S, Chen J, He X, Martin-Trevino R, Chen S, Li X, Meng X, Yu B, Wang X, Liu Y, McDermott SP, Ariazi AE, Ginestier C, Ibarra I, Ke J, Luther T, Clouthier SG, Xu L, Shan G, Song E, Yao H, Hannon GJ, Weiss ST, Wicha MS, Liu S. microRNA100 inhibits breast cancer stem cells self-renewal and tumor development. Cancer Res. 2014 Nov 15;74(22):6648-60. Epub 2014 Sep 12. PMID 25217527 Henry NL, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early stage breast cancer follow-up (Commentary). J Natl Cancer Inst. 2014 Apr;106(4). Epub 2014 Mar 13. PM24627271 Breast/GynOnc cancer researchers opened three clinical trials in FY15 and enrolled 31 patients Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2positive breast cancer: clinical validity but not utility. J Clin Oncol. 2014 Oct 10;32(29):3207-9. Epub 2014 Sep 8. PMID 25199749 Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF. Development of circulating tumor cellendocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2015 Jun 1;21(11):2487-98. Epub 2014 Nov 7. PMID 25381338 Rae JM, Leyland-Jones B, Regan M, Thompson AM. Re: Loss of heterozygosity at the CYP206 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2015 Mar 26;107(5). PMID 25814445 Schott AF, Perou CM, Hayes DF. Genome medicine in cancer: what's in a name? Cancer Res. 2015 May 15;75 (10):1930-35. Epub 2015 Apr 28. Review. PMID 25920349 Taichman LS, Inglehart MR, Giannobile WV, Braun T, Kolenic G, Van Poznak C. Periodontal health in women with early stage postmenopausal breast cancer newly on aromatase inhibitors: a pilot study. J Periodontol. 2015 Jul;86(7): 906-16. Epub 2015 Feb 12. PMID 25672657 Page 26 FY15 Division of Hematology/Oncology Annual Report Breast & GynOnc Faculty Ronald Buckanovich, MD, PhD, researches ovarian tumor vasculature and stem cell niche, with the goal of developing therapeutic treatments which disrupt cancer stem cell growth promotion pathways. He treats patients with gynecologic cancers. Monika Burness, MD, is investigating novel therapies to improve treatment options for breast cancer. She treats patients in the breast cancer clinic. Jennifer Griggs, MD, MPH, treats patients in the breast cancer clinic. Her health services research program addresses quality of care and patient-physician communication and decision making. Daniel F. Hayes, MD, Stuart B. Padnos Professor of Breast Cancer Research, is co-director of the UMCCC Breast Oncology Program. He conducts clinical and translational research to discover tumor markers and develop therapeutic treatments for patients with breast cancer. FY15 Division of Hematology/Oncology Annual Report N. Lynn Henry, MD, PhD, treats patients in the breast cancer clinic. Her research addresses why patients experience side effects from treatments, as well as potential ways to prevent or manage the side effects. Additionally, she investigates treatments for early stage and metastatic cancer. Sofia Merajver, MD, PhD, researches the molecular genetics of breast cancer, BRCA1 gene functions, angiogenesis, and cancer risk assessment. She is also the co-director of the UMCCC Breast Oncology Program and director of the Breast and Ovarian Cancer Risk and Evaluation Program. Aki Morikawa, MD, PhD, has a research interest in metastatic breast cancer, focusing on brain and leptomeningeal metastases. She is treating breast cancer patients. James Rae, PhD, is a scientist whose lab focuses on drug metabolism, pharmacogenetics, pharmacogenomics, and biomarker identification and characterization, particularly as they apply to the prediction of breast cancer treatment response. Anne Schott, MD, treats patients in the breast cancer clinic. She conducts clinical research aimed at developing novel therapies for the treatment of breast cancer. Jeffrey Smerage, MD, PhD, is Chief Medical Information Officer in the Cancer Center. He specializes in the care of breast cancer patients and conducts clinical research in the areas of tumor markers and developmental therapeutics. Catherine Van Poznak, MD, treats patients in the breast cancer clinic. Her research focuses on breast cancer and its relationship to bone including osteoporosis, biomarker identification, and bone metastases. Max Wicha, MD, Distinguished Professor of Oncology, is the founding director of the UMCCC. Dr. Wicha’s group was part of the team that first identified cancer stem cells in human breast cancers, the first in any solid tumor. His laboratory has developed many of the techniques and assays used to study these cells and to elucidate the pathways which regulate their behavior. Page 27 Sarcoma About the Program The Division of Hematology/Oncology has a strong cadre of faculty devoted to sarcoma: Drs. Laurence Baker, Rashmi Chugh, and Scott Schuetze. They specialize in the care of patients with sarcomas as well as conducting clinical research to develop novel therapeutic treatment options. The Sarcoma Survivorship Clinic was opened last year to address the unique medical and psychosocial needs of young adult and adult sarcoma survivors. This sarcoma survivorship program is a unique coordination of care between pediatric and adult sarcoma providers as well as across medical subspecialties. Our aim is to prevent morbidity/lethality of chronic medical conditions and to improve the quality of life in pediatric, adolescent, young adult, and older adult survivors. Researchers opened five clinical trials in FY15 and enrolled 36 patients Page 28 Faculty Selected Publications Cobain EF, Chinnaiyan AM, Kurzrock R, Baker LH. Genomic profiling of cancers of unknown primary site: The next steps. JAMA Oncol. 2015 Jul; 1(4): 542. PMID 26181268 Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64. Epub 2015 Apr 9. PMID 25858498 Davis EJ, Chugh R, Zhao L, Lucas DR, Biermann JS, Zalupski MM, Feng M, Wong SL, Jacobson J, Zyczynski L, Reinke D, Metko G, Baker LH, Schuetze SM. A randomised, open-label, phase II study of neo/ adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, highrisk, soft tissue sarcoma. Eur J Cancer. 2015 Jun 9. pii: S0959-8049(15)00441-4. Epub ahead of print. PMID 26066736 Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014 Aug 15;120(16):2448-56. Epub 2014 May 2. PMID 24797726 Laurence Baker, DO, Collegiate Professor of Cancer Developmental Therapeutics, conducts clinical trials and is interested in survivorship for patients with soft tissue and bone sarcomas. Rashmi Chugh, MD, treats patients with sarcoma. She is focused on clinical trials related to sarcoma and experimental therapeutics. Scott Schuetze, MD, PhD, treats patients with sarcoma. He conducts clinical research focused on the development of therapeutic treatment options for patients with sarcoma. Dr. Schuetze is also Medical Director of the UMCCC Clinical Trials Office. FY15 Division of Hematology/Oncology Annual Report Endocrine Oncology About the Program Dr. Francis Worden collaborates with colleagues across the UMCCC to treat patients with endocrine cancers. The Multidisciplinary Endocrine Oncology Clinic is one of only a few US medical centers recognized as an international center of excellence for the treatment of adrenal cancer. It is also designated as a UMHS Destination Center, an endeavor by the Health System to become the provider of choice for patients around the world. Selected Publication Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014 Nov;6(6):267-79. PMID 25364392 Researchers enrolled one patient on clinical trials during FY15 Melanoma About the Program The UMCCC Melanoma Multidisciplinary Clinic, designated as the NCI’s Midwest referral center, offers patients efficient and expedited care regardless of their disease stage. The skin cancer program was the first Destination Center in UMHS. Drs. Fecher, Lao and Redman work with colleagues across 15 departments to provide outstanding patient care and offer novel therapeutic treatments for patients with melanoma. Drs. Fecher, Lao and Redman Faculty Researchers opened three clinical trials in FY15 and enrolled 30 patients Leslie Fecher, MD, has a research and clinical focus on melanoma and other advanced cutaneous tumors. Chris Lao, MD, conducts experimental therapeutics related to melanoma chemoprevention and treats patients with melanoma. Bruce Redman, DO, conducts clinical research related to kidney cancer and melanoma to develop novel therapeutic treatment options. FY15 Division of Hematology/Oncology Annual Report Page 29 Veterans Affairs Program About the Program The Veterans Affairs Ann Arbor Healthcare System (AAVA) Hematology-Oncology Section operates in close partnership with the Division of Hematology/Oncology at the University of Michigan in all realms of their shared missions, with clinical services at the AAVA centered around Oncology and Hematology outpatient clinics and inpatient consultative services. The Section provides the programmatic foundation and leadership for the Multidisciplinary Cancer Program at the AAVA, which this year again received full accreditation from the American College of Surgeons Commission on Cancer, with full commendation in all seven available categories. The AAVA is the largest single supporter of the Hematology/Oncology Fellowship Program, enabling very diverse educational experiences characterized by immersive patient care and research experiences. The Section is actively developing its clinical research capabilities and options as it expands in response to enormous growth in patients coming from throughout Michigan and neighboring states. The faculty are engaged in diverse research pursuits including clinical, translational, outcomes and laboratory research. Page 30 Faculty Kemp Cease, MD, MBA, Section Chief, cares for patients across the spectrum of oncology. His research is in the rational design of vaccines as informed by target molecular structure. Dean Brenner, MD, holds the Kutsche Memorial Professorship of Internal Medicine, and actively conducts research in gastrointestinal oncology and cancer prevention. Megan Caram, MD, is clinically focused on genitourinary cancer, and is actively engaged in outcomes research in these patients. Scott Gitlin, MD, is engaged in the care of patients with all types of malignant and non-malignant hematologic disorders, and in advancing subspecialty education. Jon Oscherwitz, MD, is focused on laboratory research in the development of novel immunotherapeutics and vaccines for priority infectious diseases and malignancies. Tycel Phillips, MD, is a physician investigator focusing on experimental therapeutics in hematologic malignancies. Nithya Ramnath, MD, is focused on the clinical care of lung cancer patients and has research interests in biomarkers for prognostic, predictive, and translational use in lung cancer. Christine Veenstra, MD, MSHP, specializes in gastrointestinal malignancies and is working to identify factors impacting the quality of colorectal cancer care. Lisa Kujawski, MD, has a clinical and research focus on myelodysplasia, acute and chronic leukemias, and palliative medicine. FY15 Division of Hematology/Oncology Annual Report Our FY15 Faculty Roster Research Assistant Professor Longchuan Bai, PhD Jianyong Chen, PhD Jon Oscherwitz, MD Chao-Yie Yang, PhD Assistant Research Scientist Liu Liu, PhD Jianfeng Lu, PhD Ming Luo, PhD Sean P. McDermott, PhD Luke Peterson, PhD Yaping Sun, MD, PhD Research Investigator Angelo Aguilar, PhD Shoumei Bai, PhD Costanza Paoletti, MD Tomomi Toubai, PhD Haibin Zhou, PhD Yongyou Zhu, PhD Professor Laurence H. Baker, DO Dean E. Brenner, MD Kathleen A. Cooney, MD William D. Ensminger, MD, PhD* Scott D. Gitlin, MD Jennifer J. Griggs, MD Daniel F. Hayes, MD Maha Hussain, MD Gregory Kalemkerian, MD Mark S. Kaminski, MD Sofia Merajver, MD, PhD Pavan Reddy, MD Bruce G. Redman, MD Anne F. Schott, MD Scott M. Schuetze, MD Samuel M. Silver, MD, PhD David C. Smith, MD Moshe Talpaz, MD Susan Urba, MD Manuel Valdivieso, MD Shaomeng Wang, PhD Max S. Wicha, MD Francis P. Worden, MD Mark M. Zalupski, MD #New Faculty in FY15 *Emeritus Faculty FY15 Division of Hematology/Oncology Annual Report Associate Professor Dale L. Bixby, MD, PhD Paula Bockenstedt, MD Ronald J. Buckanovich, MD, PhD Erica Campagnaro, MD # Kemp B. Cease, MD Rashmi Chugh, MD Leslie Fecher, MD # Steven C. Goldstein, MD N. Lynn Henry, MD Patrick J. Hu, MD, PhD Christopher D. Lao, MD Ivan Patrick Maillard, MD Sami Malek, MD James M. Rae, PhD Nithya Ramnath, MD Jeffrey B. Smerage, MD Bryan Schneider, MD # Muneesh Tewari, MD, PhD Catherine H. Van Poznak, MD Assistant Professor Asra Z. Ahmed, MD Ajjai S. Alva, MD Grace Y. Chen, MD, PhD Mark Chiang, MD, PhD Craig E. Cole, MD Khaled Hassan, MD John C. Krauss, MD Lisa A. Kujawski, MD Qing Li, MD, PhD John M. Magenau, MD Marie Huong T. Nguyen, MD Attaphol Pawarode, MD Albert Quiery, MD Mary Riwes, DO Vaihab Sahai, MD, MS Suman Sood, MD Ryan Wilcox, MD, PhD Lecturer Patrick Burke, MD # Monika Burness, MD Megan V. Caram, MD Rami Khoriaty, MD Aki Morikawa, MD, PhD # Phillip Palmbos, MD, PhD # Brian Parkin, MD Tycel Phillips, MD Christine M. Veenstra, MD Page 31 Division of Hematology/Oncology University of Michigan Comprehensive Cancer Center 1500 E Medical Center Drive/SPC 5946 Ann Arbor, MI 48109 Acknowledgements Susan Blaisdell, layout, editing and design Professorship ceremony photos by Scott C. Soderberg, Michigan Photography Executive Officers of the University of Michigan Health System: Marschall S. Runge, M.D., Ph.D., Executive Vice President for Medical Affairs; James O. Woolliscroft, M.D., Dean, U-M Medical School; T. Anthony Denton, J.D., MHA, Acting Chief Executive Officer, U-M Hospitals and Health Centers; Kathleen Potempa, Ph.D., Dean, School of Nursing. Regents of the University of Michigan: Michael J. Behm, Mark J. Bernstein, Laurence B. Deitch, Shauna Ryder Diggs, Denise Ilitch, Andrea Fischer Newman, Andrew C. Richner, Katherine E. White, Mark S. Schlissel, ex officio. The University of Michigan, as an equal opportunity/affirmative action employer, complies with all applicable federal and state laws regarding nondiscrimination and affirmative action. The University of Michigan is committed to a policy of equal opportunity for all persons and does not discriminate on the basis of race, color, national origin, age, marital status, sex, sexual orientation, gender identity, gender expression, disability, religion, height, weight, or veteran status in employment, educational programs and activities, and admissions. Inquiries or complaints may be addressed to the Senior Director for Institutional Equity, and Title IX/Section 504/ADA Coordinator, Office for Institutional Equity, 2072 Administrative Services Building, Ann Arbor, Michigan 48109-1432, 734-7630235, TTY 734-647-1388, [email protected]. For other University of Michigan information call 734-764-1817. © 2015 Regents of the University of Michigan